NEW YORK (GenomeWeb News) – Cancer genome analysis firm Personal Genome Diagnostics said today that it will collaborate with Blueprint Medicines to search for novel kinase targets for cancer drugs.

Personal Genome Diagnostics will use exome sequencing as well as its own proprietary digital karyotyping technology, which it licensed from Johns Hopkins, to analyze copy number changes in cancer genomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.